article thumbnail

Report: Uber Artificially Pushes Pricing In San Diego

socalTECH

According to a report Wednesday from TheVerge, Uber has been keeping drivers off the road in San Diego--to force "surge" pricing on the ride service. Uber''s "surge" pricing is an algorithm-driven feature of Uber, which dramatically increases the cost of rides on its system when drivers are at a premium.

San Diego 147
article thumbnail

Reports: ServiceNow To Pitch IPO In Roadshow This Week

socalTECH

Reports this morning say that San Diego-based ServiceNow is planning to start its IPO roadshow this week, as the firm looks to brave a post-Facebook-IPO market. According to reports , the firm expects to price its IPO as late June.

Report 145
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Ligand to Spend $438M to Add Protein Maker Pfenex to Technology Lineup

Xconomy

The larger company agreed to pay $12 per share for Pfenex (NYSE American: PFNX )—a 57 percent premium to its closing price Monday. San Diego-based Ligand (NASDAQ: LGND ) generates revenue from licensing deals and royalties paid by pharmaceutical companies that use technologies it develops or acquires for their own drug research.

article thumbnail

SPECIAL REPORT: 2019 Blockchain Outlook — Reality Check

Xconomy

After a breakout year in 2017, the blockchain sector suffered a series of blows in 2018, from crashing cryptocurrency prices to increased regulatory scrutiny of crypto ventures and deepening skepticism about whether the technology was actually useful. Read more » Reprints | Share:

Report 98
article thumbnail

Drug Price Watchdog ICER Deems Amgen Migraine Drug “Cost-Effective”

Xconomy

In setting a price thousands of dollars less than expected, Amgen has won over one of the pharmaceutical industry’s fiercest drug price critics. As Amgen approached an FDA decision last month for its migraine-prevention treatment , concern mounted that the drug would come at premium. After the FDA approved erenumab last.

Pricing 75
article thumbnail

SPECIAL REPORT: 2019 Biopharma Outlook – Facing an Uncertain Future

Xconomy

biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation. In this Report, you’ll learn: The key indicators that suggest a possible downturn is on the way. After years of boom times, the U.S.

Report 83
article thumbnail

How long can Zuckerberg afford to bankroll the AR/VR market?

TechCrunch LA

The Facebook parent-company saw its stock price get bludgeoned after a bad earnings report showcased that Apple’s ad-blocking changes are shaving billions off its books and the company’s crown jewel — the Facebook platform — has stopped growing and actually shrank this quarter. Image Credits: Facebook.

Marketing 246